HER2+ esophageal carcinoma leptomeningeal metastases treated with intrathecal trastuzumab regimen
Materials & methods: We recently reported the largest trial of breast cancer patients with HER2 positive leptomeningeal metastases (LM) treated with trastuzumab. An additional treatment indication was explored as part of a single institution retrospective case series of HER2 positive esophageal...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-09-01
|
| Series: | CNS Oncology |
| Subjects: | |
| Online Access: | https://www.futuremedicine.com/doi/10.2217/cns-2022-0018 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850152217969950720 |
|---|---|
| author | Scott A Wu Dan Tong Jia Margaret Schwartz Mary Mulcahy Kuanghua Guo Matthew C Tate Sean Sachdev Nicolas Kostelecky David J Escobar Daniel J Brat Amy B Heimberger Rimas V Lukas |
| author_facet | Scott A Wu Dan Tong Jia Margaret Schwartz Mary Mulcahy Kuanghua Guo Matthew C Tate Sean Sachdev Nicolas Kostelecky David J Escobar Daniel J Brat Amy B Heimberger Rimas V Lukas |
| author_sort | Scott A Wu |
| collection | DOAJ |
| description | Materials & methods: We recently reported the largest trial of breast cancer patients with HER2 positive leptomeningeal metastases (LM) treated with trastuzumab. An additional treatment indication was explored as part of a single institution retrospective case series of HER2 positive esophageal adenocarcinoma LM (n = 2). Results: One patient received intrathecal trastuzumab (80 mg twice weekly) as part of their treatment regimen with durable long-term response and clearance of circulating tumor cells in the cerebral spinal fluid. The other patient demonstrated rapid progression and death as previously described in the literature. Conclusion: Intrathecal trastuzumab is a well-tolerated and reasonable therapeutic option worthy of further exploration for patients with HER2 positive esophageal carcinoma LM. An associative, but not a causal relationship, can be made regarding therapeutic intervention. |
| format | Article |
| id | doaj-art-71908c412a07460c9e77e4e1c8dc9f98 |
| institution | OA Journals |
| issn | 2045-0907 2045-0915 |
| language | English |
| publishDate | 2023-09-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | CNS Oncology |
| spelling | doaj-art-71908c412a07460c9e77e4e1c8dc9f982025-08-20T02:26:02ZengTaylor & Francis GroupCNS Oncology2045-09072045-09152023-09-0112310.2217/cns-2022-0018HER2+ esophageal carcinoma leptomeningeal metastases treated with intrathecal trastuzumab regimenScott A Wu0Dan Tong Jia1Margaret Schwartz2Mary Mulcahy3Kuanghua Guo4Matthew C Tate5Sean Sachdev6Nicolas Kostelecky7David J Escobar8Daniel J Brat9Amy B Heimberger10Rimas V Lukas111Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA2Department of Neurology, Northwestern University, Feinberg School of Medicine, Lou & Jean Malnati Brain Tumor Institute, Chicago, IL 60611, USA2Department of Neurology, Northwestern University, Feinberg School of Medicine, Lou & Jean Malnati Brain Tumor Institute, Chicago, IL 60611, USA3Department of Hematology & Oncology, Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA2Department of Neurology, Northwestern University, Feinberg School of Medicine, Lou & Jean Malnati Brain Tumor Institute, Chicago, IL 60611, USA4Department of Neurological Surgery, Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA5Department of Radiation Oncology, Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA6Department of Pathology, Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA6Department of Pathology, Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA6Department of Pathology, Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA4Department of Neurological Surgery, Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA2Department of Neurology, Northwestern University, Feinberg School of Medicine, Lou & Jean Malnati Brain Tumor Institute, Chicago, IL 60611, USAMaterials & methods: We recently reported the largest trial of breast cancer patients with HER2 positive leptomeningeal metastases (LM) treated with trastuzumab. An additional treatment indication was explored as part of a single institution retrospective case series of HER2 positive esophageal adenocarcinoma LM (n = 2). Results: One patient received intrathecal trastuzumab (80 mg twice weekly) as part of their treatment regimen with durable long-term response and clearance of circulating tumor cells in the cerebral spinal fluid. The other patient demonstrated rapid progression and death as previously described in the literature. Conclusion: Intrathecal trastuzumab is a well-tolerated and reasonable therapeutic option worthy of further exploration for patients with HER2 positive esophageal carcinoma LM. An associative, but not a causal relationship, can be made regarding therapeutic intervention.https://www.futuremedicine.com/doi/10.2217/cns-2022-0018circulating tumor cellsesophageal cancerHER2intrathecalleptomeningeal metastasestrastuzumab |
| spellingShingle | Scott A Wu Dan Tong Jia Margaret Schwartz Mary Mulcahy Kuanghua Guo Matthew C Tate Sean Sachdev Nicolas Kostelecky David J Escobar Daniel J Brat Amy B Heimberger Rimas V Lukas HER2+ esophageal carcinoma leptomeningeal metastases treated with intrathecal trastuzumab regimen CNS Oncology circulating tumor cells esophageal cancer HER2 intrathecal leptomeningeal metastases trastuzumab |
| title | HER2+ esophageal carcinoma leptomeningeal metastases treated with intrathecal trastuzumab regimen |
| title_full | HER2+ esophageal carcinoma leptomeningeal metastases treated with intrathecal trastuzumab regimen |
| title_fullStr | HER2+ esophageal carcinoma leptomeningeal metastases treated with intrathecal trastuzumab regimen |
| title_full_unstemmed | HER2+ esophageal carcinoma leptomeningeal metastases treated with intrathecal trastuzumab regimen |
| title_short | HER2+ esophageal carcinoma leptomeningeal metastases treated with intrathecal trastuzumab regimen |
| title_sort | her2 esophageal carcinoma leptomeningeal metastases treated with intrathecal trastuzumab regimen |
| topic | circulating tumor cells esophageal cancer HER2 intrathecal leptomeningeal metastases trastuzumab |
| url | https://www.futuremedicine.com/doi/10.2217/cns-2022-0018 |
| work_keys_str_mv | AT scottawu her2esophagealcarcinomaleptomeningealmetastasestreatedwithintrathecaltrastuzumabregimen AT dantongjia her2esophagealcarcinomaleptomeningealmetastasestreatedwithintrathecaltrastuzumabregimen AT margaretschwartz her2esophagealcarcinomaleptomeningealmetastasestreatedwithintrathecaltrastuzumabregimen AT marymulcahy her2esophagealcarcinomaleptomeningealmetastasestreatedwithintrathecaltrastuzumabregimen AT kuanghuaguo her2esophagealcarcinomaleptomeningealmetastasestreatedwithintrathecaltrastuzumabregimen AT matthewctate her2esophagealcarcinomaleptomeningealmetastasestreatedwithintrathecaltrastuzumabregimen AT seansachdev her2esophagealcarcinomaleptomeningealmetastasestreatedwithintrathecaltrastuzumabregimen AT nicolaskostelecky her2esophagealcarcinomaleptomeningealmetastasestreatedwithintrathecaltrastuzumabregimen AT davidjescobar her2esophagealcarcinomaleptomeningealmetastasestreatedwithintrathecaltrastuzumabregimen AT danieljbrat her2esophagealcarcinomaleptomeningealmetastasestreatedwithintrathecaltrastuzumabregimen AT amybheimberger her2esophagealcarcinomaleptomeningealmetastasestreatedwithintrathecaltrastuzumabregimen AT rimasvlukas her2esophagealcarcinomaleptomeningealmetastasestreatedwithintrathecaltrastuzumabregimen |